Comparative effectiveness of rheumatoid arthritis therapies

Current Rheumatology Reports

Volumn 12, Issue 5, 2010, Pages 348-354

  Finckh, Axel ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Antirheumatic therapy; Comparative effectiveness; DMARDs; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC REACTION; ARTHROPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEVER; HERPES ZOSTER; HUMAN; INFECTION; INJECTION SITE REACTION; LYMPHOMA; META ANALYSIS; NEOPLASM; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 78149468643     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0123-0     Document Type: Review

References (51)

1. Orszag PR, Ellis P: Addressing rising health care costs-a view from the Congressional Budget Office. N Engl J Med 2007, 357:1885-1887.
2. VanLare JM, Conway PH, Sox HC: Five next steps for a new national program for comparative-effectiveness research. N Engl J Med 2010, 362:970-973.
3. • Schiff M, Keiserman M, Codding C, et al: Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multicentre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008, 67:1096-1103. This is the only large, double-blind, controlled trial that directly compares two competing biologic agents. Infliximab was restricted to 3 mg/ kg. The study suggested similar efficacy of infliximab and abatacept but with a better safety profile for the latter.
4. O'Dell JR: It is the best of times; it is the worst of times: is there a way forward? A plethora of treatment options for rheumatoid arthritis, but critical trial design issues. Arthritis Rheum 2007, 56:3884-3886.
5. Donahue KE, Gartlehner G, Jonas DE, et al.: Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008, 148:124-134.
6. Boers M: A call for pragmatic treatment trials in rheumatoid arthritis. Nat Clin Pract Rheumatol 2008, 4:292-293.
7. Schwartz D, Lellouch J: Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 1967, 20:637-648.
8. Zwarenstein M, Treweek S, Gagnier JJ, et al.: Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008, 337:a2390.
9. Tunis SR, Stryer DB, Clancy CM: Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003, 290:1624-1632.
10. Furst DE, Gaylis N, Bray V, et al.: Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 2007, 66:893-899.
11. ClinicalTrials.gov: Switching anti-TNF-alpha agents in RA. Available at http://clinicaltrials.gov/ct2/show/NCT00796705? term=NCT00796705&rank=1. Accessed June 23, 2010.
12. ClinicalTrials.gov: Comparison of adalimumab and infliximab treatment of rheumatoid arthritis. Available at http://clinicaltrials.gov/ ct2/show/NCT00216177?term=Comparison+of+adalimumab+ and+infliximab+treatment+of+rheumatoid+arthritis&rank=1. Accessed June 23, 2010.
13. Grigor C, Capell H, Stirling A, et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004, 364:263-269.
14. Verstappen SM, Jacobs JW, van der Veen MJ, et al.: Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007, 66:1443-1449.
15. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005, 52:3381-3390.
16. Taylor PC: How do the efficacy and safety of abatacept and infliximab compare in the treatment of active RA? Nat Clin Pract Rheumatol 2009, 5:126-127.
17. Nixon RM, Bansback N, Brennan A: Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med 2007, 26:1237-1254.
18. Song F, Altman DG, Glenny AM, et al.: Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003, 326:472.
19. Bucher HC, Guyatt GH, Griffith LE, et al.: The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997, 50:683-691.
20. • Singh JA, Christensen R, Wells GA, et al.: A network metaanalysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009, 181:787-796. This is an "overview of reviews" using indirect comparisons. The results suggest that anakinra is less efficacious than anti-TNF agents or rituximab and that etanercept causes fewer withdrawals due to adverse events than anakinra or monoclonal antibody anti- TNF agents.
21. Gartlehner G, Hansen RA, Jonas BL, et al.: The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006, 33:2398-2408.
22. Nixon R, Bansback N, Brennan A: The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007, 46:1140-1147.
23. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al.: Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008, 9:52.
24. Chen YF, Jobanputra P, Barton P, et al.: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006, 10:iii-iv, xi-xiii, 1-229.
25. Finckh A, Bansback N, Marra CA, et al.: Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med 2009, 151:612-621.
26. Bongartz T, Sutton AJ, Sweeting MJ, et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
27. Bongartz T, Warren FC, Mines D, et al.: Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009, 68:1177-1183.
28. Leombruno JP, Einarson TR, Keystone EC: The safety of antitumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009, 68:1136-1145.
29. Salliot C, Dougados M, Gossec L: Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009, 68:25-32.
30. Suissa S: Assessing the safety of new arthritis drugs: are we there yet? J Rheumatol 2008, 35:2295-2297.
31. Zink A, Askling J, Dixon WG, et al.: European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 2009, 68:1240-1246.
32. Uitz E, Fransen J, Langenegger T, et al.: Clinical quality management in rheumatoid arthritis: putting theory into practice. Swiss Clinical Quality Management in Rheumatoid Arthritis. Rheumatology (Oxford) 2000, 39:542-549.
33. Wolfe F, Michaud K: A brief introduction to the National Data Bank for Rheumatic Diseases. Clin Exp Rheumatol 2005, 23(5 Suppl 39):S168-S171.
34. • Dixon WG, Carmona L, Finckh A, et al.: EULAR points to consider when establishing registers, and when analysing and presenting data. Ann Rheum Dis 2010 Jun 4 (Epub ahead of print). This is a good overview of important points to consider when analyzing an observational study.
35. • Mariette X, Tubach F, Bagheri H, et al.: Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010, 69:400-408. This was a population-based observational study on the incidence of lymphoma in RA patients treated with anti-TNF agents. The results suggest a lower risk of lymphoma with use of etanercept than with the monoclonal antibody anti-TNF agents.
36. Dixon WG, Hyrich KL, Watson KD, et al.: Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti- TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010, 69:522-528.
37. • Tubach F, Salmon D, Ravaud P, et al.: Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies Registry. Arthritis Rheum 2009, 60:1884-1894. This observational study and that by Dixon et al. [37] suggest a higher risk of tuberculosis with use of monoclonal antibody anti-TNF agents than with the receptor antagonist etanercept.
38. • Strangfeld A, Listing J, Herzer P, et al.: Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009, 301:737-744. This was a population-based observational study on the incidence of herpes zoster in RA patients treated with anti-TNF agents. The results suggest a lower risk with use of etanercept than with the monoclonal antibody anti-TNF agents.
39. Listing J, Strangfeld A, Kary S, et al.: Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52:3403-3412.
40. Dixon WG, Watson K, Lunt M, et al.: Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:2368-2376.
41. Finckh A, Simard JF, Gabay C, et al.: Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006, 65:746-752.
42. Finckh A, Dudler J, Wermelinger F, et al.: Influence of antiinfliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint Bone Spine 2010 May 13 (Epub ahead of print).
43. Du Pan SM, Dehler S, Ciurea A, et al.: Comparison of drug retention rates and causes of drug discontinuation between antitumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009, 61:560-568.
44. • Harrison MJ, Dixon WG, Watson KD, et al.: Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving antitumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009, 68:209-215. This was a large observational study on the incidence of psoriasis in RA patients treated with anti-TNF agents. The results suggest that the incidence of new-onset psoriasis is higher with use of adalimumab than with etanercept or infliximab.
45. • Hetland ML, Christensen IJ, Tarp U, et al.: Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO Registry. Arthritis Rheum 2010, 62:22-32. This was a population-based cohort study about the clinical effectiveness of anti-TNF agents in treatment of RA. The authors found that infliximab had the lowest rates of treatment response, disease remission, and drug adherence of the three agents; adalimumab had the highest rates of treatment response, and etanercept had the longest drug survival rates.
46. Kievit W, Adang EM, Fransen J, et al.: The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008, 67:1229-1234.
47. Kristensen LE, Saxne T, Nilsson JA, et al.: Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006, 8:R174.
48. Brocq O, Roux CH, Albert C, et al.: TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 2007, 74:148-154.
49. Finckh A, Simard JF, Duryea J, et al.: The effectiveness of antitumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. Arthritis Rheum 2006, 54:54-59.
50. Finckh A, Ciurea A, Brulhart L, et al.: B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007, 56:1417-1423.
51. • Finckh A, Ciurea A, Brulhart L, et al.: Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010, 69:387-393. This was an observational study comparing the effectiveness of two competing biologic agents in patient with inadequate response to anti-TNF agents. Rituximab appeared to be superior in patients with a history of resistance to anti-TNF therapy.